{"nctId":"NCT03524339","briefTitle":"Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery","startDateStruct":{"date":"2018-08-01","type":"ACTUAL"},"conditions":["Urinary Retention","Lower Urinary Tract Symptoms","Stress Urinary Incontinence","Pelvic Organ Prolapse"],"count":132,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo oral capsule"]},{"label":"Tamsulosin","type":"EXPERIMENTAL","interventionNames":["Drug: Tamsulosin"]}],"interventions":[{"name":"Placebo oral capsule","otherNames":[]},{"name":"Tamsulosin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must be 18 years or older as well as willing and able to provide informed consent\n* Patients must be undergoing a scheduled surgery for pelvic organ prolapse or urinary incontinence\n* Standard postoperative plan must include admission to the hospital with foley catheterization overnight the night after surgery, and planned removal of foley catheter and active voiding trial on postoperative day 1.\n\nExclusion Criteria:\n\n* Patient unable or unwilling to provide informed consent\n* Severe allergy to sulfa drugs\n* Known allergy to tamsulosin or another alpha antagonist medication\n* History of urinary retention\n* Planned bladder catheterization greater than 24 hours after surgery\n* Current use of alpha antagonist medication for hypertension\n* End stage renal or liver disease","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Postoperative Urinary Retention","description":"Failed voiding trial upon removal of catheter","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"International Prostate Symptom Score","description":"Total and subscale scores reported. Total score range 0-35, with 0 being less symptomatic and 35 being more symptomatic. Total score is sum of individual questions. Seven subgroups address incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining, nocturia. Each subgroup is scored 0-5 with 5 being most symptomatic. The last question is independent, rates quality of life from 0 (best) to 6 (worst)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Postoperative Urinary Tract Infection","description":"Treated for urinary tract infection with antibiotics or urinalysis or urine culture suggests infection.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Sent Home With Catheterization","description":"Urinary retention that required homegoing catheterization","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":62},"commonTop":["Dizziness/lightheadedness"]}}}